Poster Viewing Session IV - Investigations & Treatment

Young Investigators present their poster in a short movie and reply live to questions moderated by the session chairs.

Now Playing: Poster Viewing Session IV - Investigations & Treatment

Nov 18, 2021

Poster Viewing Session IV - Investigations & Treatment

Moderators: Hans-Peter Hartung & Oscar Fernández
  • An imaging signature in choroid plexuses in pre-symptomatic multiple sclerosis: Vito Ricigliano (Paris, France)
  • Functional brain states predict cognitive decline 5 years after a CIS: Ismail Koubiyr (Bordeaux, France)

  • Retinal thinning predicts relapse remission in relapsing multiple sclerosis: Gabriel Bsteh (Vienna, Austria)
  • Resting-state and structural MRI metrics related to fatigue in MS, MOGAD and NMOSD: Valentina Camera (Oxford, United Kingdom)
  • Natalizumab extended-interval dosing is associated with subtle inflammatory changes: Marco Pisa (Milan, Italy)
  • Visual pathway damage evolution in multiple sclerosis related acute optic neuritis: Simone Guerrieri (Milan, Italy)
  • USPIO-SWI showed vascular factors involved in "black holes" in multiple sclerosis: Li-Jie Zhang (Fujian, China)
  • Clinical and genetic features of MS in the Republic of Bashkortostan: Timur Galiulin (Ufa, Russia)
  • Humoral immune response to COVID-19 Vaccines in patients with MS on different DMTs: Alexandra Akrivaki (Athens, Greece)
  • TDCS to prevent optic nerve damage and to promote remyelination in EAE mouse model: Silvia Marenna (Milan, Italy)
  • Systemic corticosteroid therapy and visual outcome of ischemic optic neuropathy: Sofia Bezerra de Oliveira Costa (Porto, Portugal)
  • Characterisation of the immune system after ocrelizumab treatment in MS: Lien Beckers (Diepenbeek, Belgium)